Warning Letter Close-Outs – April 2022
The US FDA issued four close-out letters last month. Three resolved warning letters that had been issued to duodenoscope manufacturers about problems with Sec. 522 postmarket studies.
You may also be interested in...
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims.